Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
European Journal of Medicinal Chemistry
|
October 22, 2021
Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors
Soo-Yeon Hwang, Aarajana Shrestha, Seojeong Park, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 16, 2025
Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation
Kyung-Hwa Jeon, Seojeong Kim, Seojeong Park, et al.
Journal of Advanced Research
|
August 13, 2022
Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers
Soo-Yeon Hwang, Seojeong Park, Hyunji Jo, et al.
Molecular Cancer
|
May 9, 2025
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRAS<sup>G13D</sup> colorectal cancer
Soo-Yeon Hwang, Yoojeong Seo, Seojeong Park, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
European Journal of Medicinal Chemistry
|
October 22, 2021
Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors
Soo-Yeon Hwang, Aarajana Shrestha, Seojeong Park, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 16, 2025
Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation
Kyung-Hwa Jeon, Seojeong Kim, Seojeong Park, et al.
Journal of Advanced Research
|
August 13, 2022
Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers
Soo-Yeon Hwang, Seojeong Park, Hyunji Jo, et al.
Molecular Cancer
|
May 9, 2025
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRAS<sup>G13D</sup> colorectal cancer
Soo-Yeon Hwang, Yoojeong Seo, Seojeong Park, et al.
Page
of 2